Under the Enterprise Act 2016, the HTA and all other statutory regulators have a duty to report against the Government’s Business Impact Target. The target for the 2015-2020 Parliament is a £10 billion reduction in the cost of regulation to business.
The objectives of the BIT are to:
The Government has set out the need for greater transparency to enable the public to hold public bodies and politicians to account. This includes commitments relating to public expenditure, intended to help reduce the deficit and achieve better value for money.
You can browse and read previous FOI responses below.
For FOI responses before 2018, please see the national archive website.
The HTA has a responsibility to make its information available in accordance with the Freedom of Information Act. Before making a Freedom of Information request please take the time to check that it is not already available on one of these pages:
The duties of the Remuneration Committee are to:
The Authority – the HTA’s non-executive board – is made up of a Chair and 11 Members who are appointed by the Secretary of State for Health, with the exception of one Member appointed by the Welsh Minister and one by the Minister in Northern Ireland.
The six-month phase for Human Application sector establishments to comply with new import and export licensing requirements ended on 1 July 2021.
If you import or export tissues and cells between GB and the EEA, you may need a suitable HTA licence in place covering this activity. If you think this applies to you and you have not previously contacted us to discuss your arrangements, please contact us as soon as possible.
The HTA-related licensing changes introduced at the end of the UK Transition Period affect some establishments that previously did not require an HTA licence for importing or exporting human tissues and cells for human application.
Examples of human application include: